Skip to content
Sign in

GNOM · NASDAQ · ETF

Global X Genomics & Biotechnology ETF (GNOM) Price, Holdings & Fees

$564.67−0.27%−$1.51End-of-day price as of Oct 9, 2026

Global X Genomics & Biotechnology ETF (GNOM) closed at $564.67 on Oct 9, 2026, down 0.27% from the previous close of $566.18.

Share price, past year

1Y +21.59%

52-week range $458.90 – $578.53. Daily closing prices.
Monthly closing prices
Last closing price of each month
DateClose
Oct 9, 2026$564.67
Sep 30, 2026$576.12
Aug 31, 2026$560.21
Jul 31, 2026$569.80
Jun 30, 2026$551.05
May 29, 2026$518.13
Apr 30, 2026$497.23
Mar 31, 2026$516.67
Feb 27, 2026$537.49
Jan 30, 2026$496.68
Dec 31, 2025$509.81
Nov 28, 2025$507.26
Oct 31, 2025$467.16

Key statistics

Expense ratio
0.50%
as of Mar 31, 2026
Net assets
$55.8M
as of May 31, 2026
Holdings
51
as of May 31, 2026
52-week range
$458.90 – $578.53

Global X Genomics & Biotechnology ETF's expense ratio is 0.50%: $50.00 a year on $10,000 invested.

Holdings

Global X Genomics & Biotechnology ETF held 51 investments worth $55.79M as of May 31, 2026. Its largest holding was GUARDANT HEALTH, INC., at 5.59% of the fund.

Global X Genomics & Biotechnology ETF largest holdings by share of net assets
#Holding% of fundValue
1GUARDANT HEALTH, INC.5.59%$3.12M
2ILLUMINA, INC.4.82%$2.69M
3NATERA, INC.4.15%$2.32M
4BIOMARIN PHARMACEUTICAL INC.4.09%$2.28M
5ARROWHEAD PHARMACEUTICALS, INC.4.07%$2.27M
6Legend Biotech Corp4.05%$2.26M
7Praxis Precision Medicines Inc4.01%$2.24M
8Twist Bioscience Corp3.97%$2.21M
9VERTEX PHARMACEUTICALS INCORPORATED3.95%$2.20M
10CRISPR Therapeutics AG3.85%$2.15M
11Veracyte Inc3.64%$2.03M
12Qiagen N.V.3.54%$1.97M
13BioNTech SE3.41%$1.90M
14BIO-TECHNE CORPORATION3.41%$1.90M
15MODERNA, INC.3.28%$1.83M
1610X Genomics Inc3.23%$1.80M
17Beam Therapeutics Inc3.09%$1.72M
18BNYREPOS3.05%$1.70M
19ELI LILLY AND COMPANY2.32%$1.29M
20Ultragenyx Pharmaceutical Inc2.25%$1.26M
21CARIS LIFE SCIENCES, INC.2.03%$1.13M
22Genscript Biotech Corp2.00%$142.27K
23BillionToOne Inc1.97%$1.10M
24GILEAD SCIENCES, INC.1.95%$1.09M
25ASTRAZENECA PLC1.83%$1.38M

Top 25 of 51 holdings, as of May 31, 2026. Percentages are of the fund's net assets.

What the fund owns

Global X Genomics & Biotechnology ETF holdings by asset type
Asset type% of fund
Stocks99.90%
Repurchase agreements3.05%
Global X Genomics & Biotechnology ETF holdings by country, largest 3
Country% of fund
United States99.12%
Hong Kong2.00%
United Kingdom1.83%

Shares of net assets from the fund's N-PORT report. Funds that borrow can add up to more than 100%, with borrowing (such as repurchase agreements) shown as a negative share.

Monthly total returns

Over the 3 months to May 31, 2026, Global X Genomics & Biotechnology ETF's total return was +3.68%, as reported to the SEC.

Global X Genomics & Biotechnology ETF monthly total returns
MonthTotal return
May 31, 2026−8.57%
Apr 30, 2026+3.45%
Mar 31, 2026+9.61%

The fund's own total returns as reported to the SEC (N-PORT), including reinvested distributions. Not the sample prices above.

Fund profile

Name
Global X Genomics & Biotechnology ETF
Ticker
GNOM
Exchange
NASDAQ
Fund type
ETF
Trust
Global X Funds
SEC series ID
S000062676
SEC CIK
0001432353
Fractional shares
Yes

Recent SEC filings

Shareholder reports and prospectuses are filed by Global X Funds, the trust behind Global X Genomics & Biotechnology ETF, and cover all of its funds.

Frequently asked questions

What is GNOM's price?

Global X Genomics & Biotechnology ETF (GNOM) closed at $564.67 on Oct 9, 2026, down 0.27% from the previous close of $566.18.

What is GNOM's expense ratio?

Global X Genomics & Biotechnology ETF's expense ratio is 0.50%: $50.00 a year on $10,000 invested.

What does GNOM hold?

Global X Genomics & Biotechnology ETF held 51 investments worth $55.79M as of May 31, 2026. Its largest holding was GUARDANT HEALTH, INC., at 5.59% of the fund. Its five largest holdings were GUARDANT HEALTH, INC., ILLUMINA, INC., NATERA, INC., BIOMARIN PHARMACEUTICAL INC., ARROWHEAD PHARMACEUTICALS, INC..

How has GNOM performed?

Over the 3 months to May 31, 2026, Global X Genomics & Biotechnology ETF's total return was +3.68%, as reported to the SEC.

Sources and methodology

Holdings, net assets and monthly returns come from the fund's N-PORT filing with the SEC, as of May 31, 2026 (filed Jul 29, 2026). The expense ratio is from the fund's prospectus or shareholder report, as of Mar 31, 2026. Prices are generated sample data for development. Data sources and disclosures